Is this Seattle Penny Pot Stock a Potential Blockbuster?
A small, rapidly expanding Seattle cannabis company is gaining attention from investors. Founded by two cannabis veterans, the company has increased sales 8-fold since inception. Now selling for less than $1 per share, this is an opportunity to acquire thousands of shares – a potential windfall.
Get Free Report on #1 Cannabis Pick for 2021
James E. Levine, insider at Cardiff Oncology
James E. Levine Insider Alerts

Get notified the next time James E. Levine buys or sells Cardiff Oncology stock. Enter your email address below to get our daily insider buying and selling report.

James E. Levine Insider Information

Mr. Levine has served as Chief Financial Officer since 2021. Mr. Levine has extensive corporate and investment banking experience with both private and public biotechnology and pharmaceutical companies. Prior to joining Cardiff Oncology, Mr. Levine served as CFO of Cidara Therapeutics, where he led the financial aspects of important pre-clinical and clinical collaborations with Janssen Pharmaceuticals (part of Johnson & Johnson) and Mundipharma with a combined value of over $1.3 billion. Previously, Mr. Levine was the president and chief executive officer of Sapphire Energy Inc., a private industrial biotechnology company that was sold to two private investor groups. He also previously served in the same roles at Verenium Corp., where he negotiated six product commercialization partnerships and asset sales, before selling the company to BASF. He also previously was a managing director in the investment banking division of Goldman Sachs & Co., serving in its healthcare and energy groups.

Mr. Levine earned an MBA in finance from the Wharton School of the University of Pennsylvania and a BA in economics from Brandeis University.

What is James E. Levine's net worth?

The estimated net worth of James E. Levine is at least $27,000.00 as of September 10th, 2021. Mr. Levine owns 5,000 shares of Cardiff Oncology stock worth more than $27,000 as of November 30th. This net worth evaluation does not reflect any other investments that Mr. Levine may own. Learn More.

How do I contact James E. Levine?

The corporate mailing address for Mr. Levine and other Cardiff Oncology executives is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. Cardiff Oncology can also be reached via phone at (858) 952-7570 and via email at [email protected]

Has James E. Levine been buying or selling shares of Cardiff Oncology?

James E. Levine has not been actively trading shares of Cardiff Oncology during the last quarter. Most recently, on Friday, September 10th, James E. Levine bought 30,000 shares of Cardiff Oncology stock. The stock was acquired at an average cost of $6.47 per share, with a total value of $194,100.00. Following the completion of the transaction, the chief financial officer now directly owns 5,000 shares of the company's stock, valued at $32,350.

Who are Cardiff Oncology's active insiders?

Cardiff Oncology's insider roster includes John Brancaccio (Director), Mark Erlander (CEO), Vicki Kelemen (COO), James Levine (CFO), Rodney Markin (Director), and Gary Pace (Director).

Are insiders buying or selling shares of Cardiff Oncology?

In the last year, Cardiff Oncology insiders bought shares 8 times. They purchased a total of 72,325 shares worth more than $524,808.70. The most recent insider tranaction occured on September, 21st when Director Gary W Pace bought 30,000 shares worth more than $202,500.00. Insiders at Cardiff Oncology own 4.6 % of the company.

Information on this page was last updated on 9/21/2021.

James E. Levine Insider Trading History at Cardiff Oncology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/10/2021Buy30,000$6.47$194,100.005,000View SEC Filing Icon  
See Full Table

James E. Levine Buying and Selling Activity at Cardiff Oncology

This chart shows James E Levine's buying and selling at Cardiff Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cardiff Oncology Company Overview

Cardiff Oncology logo
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $5.40
Low: $5.32
High: $5.69

50 Day Range

MA: $6.22
Low: $5.23
High: $7.39

2 Week Range

Now: $5.40
Low: $4.88
High: $25.50

Volume

465,274 shs

Average Volume

1,547,411 shs

Market Capitalization

$213.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61
Economic and National Security Threats Create Lithium Bonanza
The U.S. and China are fighting for new sources of lithium – the linchpin of clean energy. Lithium mining operations have been declared a national emergency. Biden has ordered America's lithium supply chain to be strengthened and investors in lithium exploration companies are rejoicing. We may be entering a decades-long lithium bull run. You don't want to miss it.
Click here for the full story.